Profile data is unavailable for this security.
About the company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
- Revenue in USD (TTM)0.00
- Net income in USD-305.52m
- Incorporated2020
- Employees5.00
- LocationAeon Biopharma Inc5 Park Plaza, Suite 1750IRVINE 92614United StatesUSA
- Phone+1 (949) 354-6499
- Fax+1 (302) 655-5049
- Websitehttps://aeonbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equillium Inc | 42.62m | -8.32m | 27.01m | 45.00 | -- | 1.20 | -- | 0.6337 | -0.2377 | -0.2377 | 1.20 | 0.6333 | 0.8388 | -- | 8.85 | 968,704.60 | -16.37 | -46.81 | -29.58 | -57.36 | -- | -- | -19.52 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -15.00m | 27.21m | 20.00 | -- | 2.11 | -- | -- | -7.69 | -7.69 | 0.00 | 0.6954 | 0.00 | -- | -- | 0.00 | -69.12 | -- | -92.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -8.11m | 27.34m | 8.00 | -- | 2.95 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -31.75m | 27.48m | 17.00 | -- | 1.57 | -- | -- | -1.64 | -1.64 | 0.00 | 0.6921 | 0.00 | -- | -- | 0.00 | -87.09 | -57.10 | -127.72 | -71.20 | -- | -- | -- | -- | -- | -368.16 | 0.3861 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| ImmuCell Corp | 23.22m | -4.05m | 27.73m | 74.00 | -- | 1.18 | -- | 1.19 | -0.521 | -0.521 | 2.99 | 2.99 | 0.5409 | 2.32 | 13.47 | 293,961.10 | -9.43 | -5.16 | -10.50 | -5.53 | 26.05 | 40.04 | -17.44 | -12.64 | 0.7668 | -7.43 | 0.3243 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 28.42m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
| IGC Pharma Inc | 1.06m | -13.30m | 28.89m | 67.00 | -- | 3.67 | -- | 27.21 | -0.2104 | -0.2104 | 0.0167 | 0.1042 | 0.0809 | 0.2028 | 8.40 | 15,850.75 | -101.29 | -42.46 | -122.91 | -46.07 | 60.36 | 20.95 | -1,252.64 | -730.00 | 1.16 | -- | 0.0173 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| Aeon Biopharma Inc | 0.00 | -305.52m | 29.64m | 5.00 | -- | -- | -- | -- | -8.40 | -8.40 | 0.00 | -0.7144 | 0.00 | -- | -- | 0.00 | -6,646.10 | -- | -- | -- | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -17.09m | 29.66m | 31.00 | -- | -- | -- | -- | -0.4891 | -0.4891 | 0.00 | -0.4202 | 0.00 | -- | -- | 0.00 | -152.35 | -- | -4,151.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 29.75m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -11.45m | 29.91m | 32.00 | -- | 0.5039 | -- | -- | -1.22 | -1.22 | 0.00 | 5.85 | 0.00 | -- | -- | -- | -16.04 | -31.68 | -16.57 | -33.95 | -- | -- | -- | -56,271.43 | -- | -37.80 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 30.22m | 4.00 | -- | 8.68 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 30.78m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Longeveron Inc | 1.23m | -27.90m | 31.59m | 23.00 | -- | 1.42 | -- | 25.70 | -8.75 | -8.75 | 0.3641 | 1.55 | 0.0674 | -- | 7.83 | 53,434.78 | -101.98 | -63.15 | -127.46 | -75.68 | 58.99 | 33.70 | -1,513.83 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Iterum Therapeutics PLC | 0.00 | -28.34m | 31.79m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.658 | 0.00 | -- | -- | 0.00 | -86.93 | -118.12 | -150.76 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 2.06 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| SAB Biotherapeutics Inc | 2.78m | -40.32m | 32.39m | 57.00 | -- | 0.7024 | -- | 11.65 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
Data as of Nov 09 2024. Currency figures normalised to Aeon Biopharma Inc's reporting currency: US Dollar USD
13.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Asset Management Partners, Inc.as of 30 Jun 2024 | 3.68m | 9.30% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 744.10k | 1.88% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 269.61k | 0.68% |
| Ikarian Capital LLCas of 30 Jun 2024 | 257.98k | 0.65% |
| Geode Capital Management LLCas of 30 Jun 2024 | 186.86k | 0.47% |
| Formidable Asset Management LLCas of 30 Jun 2024 | 113.64k | 0.29% |
| Davidson Kempner Capital Management LPas of 30 Jun 2024 | 90.05k | 0.23% |
| The Caprock Group LLCas of 30 Sep 2024 | 62.69k | 0.16% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 60.95k | 0.15% |
| Boothbay Fund Management LLCas of 30 Jun 2024 | 55.06k | 0.14% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
